Pathological mechanisms of osteoarthritis in the network of geriatric comorbidities: Emerging insights from organs-crosstalk Authors: Hai-Yang Hu, Hao Yin, Yi-Wei Liu, Zhen-Xing Wang, Hui Xie Published: 2026 ABSTRACT AbstractWith the rapid progression of global population aging, osteoarthritis (OA), a common degenerative joint disease, increasingly affects the quality of life and functional status of the elderly. OA often coexists with other chronic diseases in elderly patients, forming a complex comorbidity network. However, the interactions between OA and other geriatric comorbidities and their effects on disease progression have not been fully explored. This review investigates the pathological mechanisms of OA within the geriatric comorbidity network, focusing on its bidirectional interactions with osteoporosis, obesity, diabetes, and hypertension, and examines the effects of commonly used medications in elderly patients with comorbidities. The findings reveal that these chronic conditions contribute to OA through mechanisms such as mechanical stress, metabolic dysregulation, and inflammation. Additionally, OA exacerbates other comorbidities, further worsening the overall health of patients. The review emphasizes the need for integrated treatment strategies that address both OA and its comorbidities, and highlights the importance of further research into the molecular interactions between OA and comorbidities for more effective treatment strategies, particularly targeting shared pathways.Translational Potential of this Article: This review defines osteoarthritis (OA) as a systemic disease driven by organ crosstalk within the geriatric comorbidity network. Interactions among bone, adipose, vascular, and metabolic systems converge on shared pathways, including inflammation, metabolic dysregulation, and biomechanical imbalance. This framework supports a shift toward mechanism-based, multi-organ management and highlights opportunities for drug repurposing, biomarker-guided risk stratification, and precision medicine, ultimately improving outcomes in elderly patients with OA and multimorbidity.Keywords: Osteoarthritis, Geriatric comorbidities, Pathological mechanisms, Chronic diseases, Treatment strategies, Organ crosstalk Introduction With the rapid progression of global population aging, the health issues of the elderly have increasingly become a focal point in the field of public health. According to the World Health Organization (WHO) forecast, the proportion of the population aged 60 and above will continue to rise, and it is expected to account for more than 22% of the global population by 2050 [1]. This trend has led to a significant increase in the prevalence of chronic diseases among the elderly, imposing substantial burdens on social healthcare systems. Osteoarthritis (OA), characterized by progressive cartilage degradation, synovial inflammation, and osteophyte formation, is a leading cause of pain and disability among older adults [2]. Its prevalence approaches 50% in individuals over 60 years, with radiographic evidence observed in up to 80% of cases [3], with recent data underscoring age-specific comorbidity risks. Geriatric comorbidity refers not only to the coexistence of multiple chronic diseases in elderly individuals, but also to their complex biological and clinical interactions driven by aging [4]. Within this context, OA rarely occurs in isolation but instead coexists with conditions such as hypertension, diabetes, and cardiovascular disease, forming a complex and interdependent comorbidity network. Emerging evidence indicates that this clustering reflects shared aging-driven biological mechanisms rather than coincidental co-occurrence [5,6]. Aging reshapes disease biology through interconnected processes such as cellular senescence, immunosenescence, and mitochondrial dysfunction, leading to impaired tissue repair and increased vulnerability to stress [7]. A hallmark of aging is inflammaging, characterized by chronic low-grade inflammation and accumulation of senescent cells with a SASP phenotype [7,8]. Such aging-related alterations endow chronic diseases in the elderly with distinct pathophysiological features that are rarely seen in young adults, including systemic metabolic imbalance, disrupted inter-organ crosstalk, complex multimorbidity interactions, frequent polypharmacy, and concurrent geriatric syndromes such as sarcopenia, frailty, and cognitive decline [9]. These processes are interconnected through inter-organ signaling networks linking metabolic dysfunction, vascular impairment, and musculoskeletal degeneration. From this systemic perspective, OA should be viewed not merely as a localized joint disease, but as a manifestation of dysregulated organ crosstalk in the aging organism. Although existing studies have explored the etiology and treatment of OA, the interactions between OA and other common chronic diseases in elderly comorbidity networks, and their impact on disease progression, remain underexplored areas requiring further investigation. Elderly patients with comorbidities often require long-term use of multiple medications, which not only play a critical role in treating other chronic diseases but may also influence the progression and treatment of OA [10]. For example, nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to alleviate pain and inflammation in OA, but their long-term use may lead to adverse effects [10], especially in elderly patients with kidney or cardiovascular diseases. In addition, commonly used medications for other geriatric comorbidities, such as metformin, GLP-1 agonists, calcitonin, and bisphosphonates, have recently been found to potentially modulate OA. Therefore, this review aims to explore the mechanisms by which OA functions within the geriatric comorbidity network, reveal its interactions with other common chronic diseases, and deeply analyze the potential mechanisms of commonly used drugs in elderly comorbidity patients and their effects when used in combination, emphasizing therapeutic repurposing and emerging molecular targets. Epidemiological characteristics of geriatric comorbidity globally Epidemiological characteristics of OA and geriatric comorbidity Geriatric comorbidity is defined as the coexistence of two or more chronic diseases. According to statistics from the World Health Organization (WHO), approximately 50%-80% of the global population aged 65 years and above exhibit this phenomenon, with significant variations observed based on age and economic development level: A cross-country study, covering 33 countries, revealed that 83% of middle-aged and elderly individuals in high-income countries suffer from one or more “physical-mental-cerebral” diseases, with the comorbidity prevalence rate reaching 24.5%; in upper-middle-income countries (including China), the proportion of people with one or more “physical-mental-cerebral” diseases is 80%, and the comorbidity prevalence rate is even higher at 33.9%; while in low- and middle-income countries such as India, the comorbidity prevalence rate is only 8.1%, the risk of comorbidity among individuals with lower socioeconomic status is 11.45 times higher than that among those with higher socioeconomic status [11]. Age shows a clear exponential correlation with the number of comorbid diseases: Approximately 65% of individuals aged 65-84 years have two or more chronic diseases, and this proportion rises to 82% among the elderly population aged 85 years and above, among whom nearly two-thirds suffer from three or more diseases [12]. The patterns of disease combinations exhibit significant heterogeneity: In developed countries, the “classic triad” of cardiovascular diseases, metabolic diseases, and musculoskeletal system diseases is the most common; in developing countries, there are regional specificities—upper-middle-income countries such as China have shown disease combinations similar to those in developed countries, while countries like India are still characterized by the coexistence of infection-related sequelae and malnutrition-related diseases. Furthermore, the “physical-mental-cerebral comorbidity” pattern (somatic diseases + psychological disorders + cognitive decline) accounts for more than 50% of the global middle-aged and elderly population, becoming a crucial factor affecting healthy life expectancy [11]. Epidemiological features of global OA OA has become the fourth leading cause of disability globally. In 2020, the number of OA patients worldwide reached 595 million (accounting for 7.6% of the global population), representing a 132.2% increase compared with 1990. According to projections from the Global Burden of Disease Study (GBD), by 2050, the number of knee OA cases will increase by 74.9%, hip OA cases by 78.6%, hand OA cases by 48.6%, and cases of other types of OA by as much as 95.1%. Among the population aged 60 years and above, approximately 70% have radiological evidence of osteoarthritic degeneration, with 10%-30% of them presenting clinical symptoms. Specifically, the prevalence of symptomatic OA in individuals aged 60 years and above is 10%-15%, while the radiological positivity rate is as high as 80% [13,14]. The epidemiological characteristics of OA exhibit significant differences across gender, age, and region. In terms of gender, females account for 62% of all OA patients. Before the age of 45, the prevalence of OA is slightly higher in males; however, after the age of 45, the prevalence in females rises significantly. Particularly, postmenopausal females face a sharply increased risk of knee and hand OA, which is associated with the weakened cartilage protective effect caused by decreased estrogen levels. In terms of regional distribution, the prevalence is the highest in high-income Asia–Pacific regions (8632.7 per 100,000 population) and the lowest in Southeast Asia (5677.4 per 100,000 population). Due to high obesity rates (elevated BMI is associated with 20.4% of OA cases) and population aging, developed countries have a significantly higher prevalence of knee OA than developing countries. In contrast, Asian countries such as China and South Korea have witnessed a rapid increase in the burden of knee OA with the acceleration of urbanization, making it a regional-specific health issue [13,14]. Epidemiological correlation of geriatric comorbidity and OA Geriatric comorbidity and OA are significantly correlated in the elderly population. As a common chronic disease within geriatric comorbidity, OA, particularly in individuals aged 65 and older, often coexists with other chronic conditions, creating a complex disease burden. This coexistence not only exacerbates the patient's health status but also significantly impacts their quality of life and functional capacity. Research has shown that OA has a high comorbidity rate with other common chronic conditions in the elderly, such as cardiovascular diseases, diabetes, osteoporosis, and cognitive impairments [15]. For instance, the prevalence of cardiovascular diseases is higher in OA patients than in the general elderly population, which is attributed to limitations in mobility and the prolonged inflammatory response affecting the cardiovascular system. The correlation between OA and diabetes is similarly significant, especially as obesity, a risk factor for diabetes, is closely associated with the occurrence of knee OA [16]. Additionally, the chronic pain and functional impairments caused by OA are intertwined with depression, anxiety, and other mental health disorders in the elderly, which increases the psychological burden and further impacts overall health (Fig. 1)[17]. Epidemiological characteristics of Osteoarthritis (OA) in geriatric comorbidity network. Mechanism of the influence of geriatric comorbidity on OA The impact of osteoporosis on OA Osteoporosis (OP) is another common degenerative bone disease, apart from OA, often found in the elderly, especially postmenopausal women. Its main characteristic is the reduction of bone mineral density (BMD), which increases the susceptibility to fractures, significantly affecting the quality of life and health management of the elderly [18,19]. Studies have shown that in OA models accompanied by osteoporosis, the density and trabecular structure of subchondral bone undergo significant changes, with increased activity of subchondral osteoclasts. The heightened osteoclast activity may lead to further damage to the subchondral bone, accelerating the pathological progression of OA [20,21]. This indicates a close relationship between osteoporosis and OA in terms of pathogenesis, with osteoporosis promoting the occurrence and development of OA through various mechanisms, including subchondral microdamage and increased porosity in early OA stages. Firstly, osteoporosis leads to reduced bone density and weakened bone strength, causing uneven pressure distribution in joints when bearing weight and daily stresses [22]. In particular, in weight-bearing joints like the knee and hip, prolonged local pressure is concentrated on weak bone areas, resulting in excessive cartilage wear and inducing OA. Additionally, osteoporosis reduces joint stability, as weakened bone strength affects the attachment and function of the surrounding ligaments and muscles, increasing the risk of abnormal displacement and twisting of the joint during movement, leading to damage to joint structures such as cartilage and menisci [23]. In terms of bone metabolism, osteoporosis causes significant changes in subchondral bone, including enhanced bone resorption, thinning and narrowing of trabeculae, and even fractures, with the expansion of the bone marrow cavity. These microstructural changes affect the nutrient supply and mechanical transmission of the articular cartilage, making it more susceptible to damage and degeneration, thus accelerating the onset of OA. Furthermore, the continuous loss of bone mass due to osteoporosis, especially at the joint margin, leads to the formation of osteophytes in response to abnormal stress. While osteophyte formation attempts to repair bone damage, it further disrupts joint structure, causing pain and limited movement. Moreover, in the state of osteoporosis, the enhanced activity of osteoclasts promotes the release of inflammatory factors such as and interleukin-1 (IL-1)、interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) [24,25]. These inflammatory factors may spread to the articular cartilage, triggering joint inflammation, resulting in joint pain, swelling, and dysfunction. The inflammatory response not only affects cartilage metabolism and repair but also accelerates cartilage degeneration. Additionally, bone metabolism disorders and inflammation may activate the immune system [26,27], with immune cells gathering in the joint tissue and releasing more inflammatory mediators, exacerbating joint damage and creating a vicious cycle, further driving the progression of OA. In conclusion, although osteoporosis accelerates the onset and progression of OA through mechanisms such as bone metabolism disorders, mechanical stress changes, and inflammatory responses, the specific mechanisms are becoming clearer with recent insights into their interplay. Current research is limited, and further in-depth studies are needed to explore its underlying biological mechanisms. The impact of obesity on OA Obesity holds significant clinical importance in geriatric comorbidity, acting not only as an independent risk factor for various chronic diseases but also potentially exacerbating the occurrence and progression of comorbidities through complex pathophysiological mechanisms. Obesity has long been considered a major and potentially avoidable risk factor for OA, with numerous epidemiological studies showing its multiple impacts on the incidence, progression, and severity of OA symptoms [28,29]. The role of obesity and overweight in the progression of OA is among the most researched topics in OA studies [30]. The most direct impact of weight gain on OA is the increased mechanical load on joints, particularly weight-bearing joints such as the knees and hips. Existing studies have demonstrated a positive correlation between higher body weight and joint load, with obese individuals experiencing much greater mechanical stress on joints during weight-bearing compared to those with normal body weight [31]. In a prospective study, individuals with a BMI ≥30 kg/m2 had a sevenfold higher incidence of knee OA compared to those with a BMI ≤25 kg/m2 [32,33]. Furthermore, the degree of obesity is related to a dose-response relationship with knee OA. In obese populations, for every one unit increase in BMI above 27 kg/m2, the prevalence of OA increases by 15% [34]. Excess weight not only increases the mechanical load on joints but may also lead to joint misalignment, further exacerbating mechanical stress and cartilage degeneration, which in turn promotes the development of OA [35,36]. However, mechanical loading alone cannot fully explain the relationship between obesity and OA. Increasing evidence indicates that obesity profoundly alters musculoskeletal biomechanics through its effects on muscle function and movement patterns. Obese individuals often exhibit reduced muscle strength, particularly in the quadriceps, which plays a critical role in stabilizing the knee joint [[37], [38], [39]]. This reduction in muscular support impairs shock absorption and increases joint instability during movement. In addition, obesity is frequently associated with altered gait patterns, including reduced walking speed, prolonged stance phase, and abnormal joint alignment, all of which contribute to uneven load distribution across articular surfaces [40]. In elderly individuals, obesity often coexists with age-related sarcopenia (sarcopenic obesity), a condition characterized by reduced muscle mass and function alongside excess adiposity. This combination further exacerbates mechanical imbalance by simultaneously increasing joint loading and weakening dynamic joint stabilization, thereby accelerating cartilage degeneration [37]. These biomechanical alterations, together with increased joint loading, create a more complex mechanical environment that promotes structural damage in both cartilage and subchondral bone. At the cellular level, these combined mechanical and biomechanical stresses directly affect chondrocytes and subchondral bone remodeling. Increased mechanical stress has been shown to induce chondrocyte degeneration through the activation of pro-inflammatory mediators such as IL-1β, TNF-α, COX-2, and matrix metalloproteinases (MMPs), as well as signaling pathways including FAK, ERK, JNK, p38, and NF-κB [41,42]. Moreover, research indicates that excessive mechanical load can trigger the process of chondrocyte senescence, a phenomenon particularly prominent in obese patients, further accelerating the onset of OA [43]. Obesity not only impacts cartilage through mechanical load but also significantly affects subchondral bone. Joint overloading caused by obesity often leads to thickening and sclerosis of the subchondral cortical bone, thereby worsening cartilage damage. Studies have shown that mechanical overload induces a sclerosis response in subchondral bone, making it stiffer and impairing its normal physiological function with cartilage [44]. Additionally, obesity may alter osteoblastic function in subchondral bone through pro-inflammatory factors, triggering either non-sclerotic or sclerotic bone remodeling in the subchondral bone, a process that further exacerbates OA susceptibility by increasing the expression of inflammatory factors like IL-6, IL-8, COX-2, RANKL, MMP-3, and MMP-9, while reducing the expression of osteoprotegerin (OPG) [45]. Although obesity directly contributes to the occurrence and progression of OA by increasing mechanical load on joints, this mechanism alone cannot fully explain how obesity increases the risk of OA in non-weight-bearing joints, such as the fingers and wrists [46]. Increasing evidence suggests that obesity not only exerts its effects through local mechanical mechanisms but also increases the risk of OA through systemic, non-mechanical pathways. Notably, sustained low-grade inflammation is considered an important pathophysiological mechanism of obesity-related OA [47]. In obesity, the immune system is activated by pro-inflammatory factors secreted by adipose tissue, resulting in a persistent systemic chronic low-grade inflammatory response. Immune cells, particularly macrophages, play a crucial role in the relationship between obesity and OA [48,49]. In obese individuals, macrophages in adipose tissue gradually shift from the M2 (anti-inflammatory) phenotype to the M1 (pro-inflammatory) phenotype. The activation of M1 macrophages is closely linked to the release of a series of pro-inflammatory factors (such as TNF-α, IL-1β, IL-6) and chemokines (e.g., MCP-1, CXCL-9), which not only worsen cartilage damage in OA but also accelerate the OA process by promoting inflammation in the synovium and subchondral bone [30,50,51]. The activation of M1 macrophages not only intensifies the inflammatory response of the immune system but also promotes the formation of osteophytes and the degradation of the cartilage matrix through direct action on chondrocytes and osteoblasts [52,53]. Furthermore, obesity activates the immune system, facilitating the infiltration of other immune cells such as T cells and B cells, which further exacerbates chronic inflammation in OA. These immune cells secrete various cytokines and chemokines, further promoting synovial inflammation, cartilage degradation, and changes in bone structure [54,55]. The impact of obesity on OA is not limited to mechanical load and inflammatory responses; it also exacerbates OA progression at the molecular level through adipokines. Adipokines are bioactive substances secreted by adipose tissue, which act via endocrine, paracrine, and autocrine mechanisms in multiple systems [56]. In obesity, levels of adipokines such as leptin, adiponectin, resistin, and visfatin are elevated and have been shown to be closely associated with the onset, progression, and severity of OA symptoms [57,58]. For instance, leptin, the first identified adipokine, is significantly elevated in both obese and OA patients. Studies show that leptin levels in OA patients are positively correlated with the severity of the disease and pain levels [57,59]. Leptin promotes the release of pro-inflammatory cytokines by regulating the function of chondrocytes and synovial cells, thereby facilitating the degradation of the cartilage matrix. Additionally, adiponectin, another important adipokine, has shown controversial effects on OA progression. While some studies suggest that adiponectin may have a protective role in OA, its exact mechanism remains unclear and requires further investigation [60]. Adiponectin may, to some extent, regulate OA progression by reducing the release of pro-inflammatory cytokines and increasing the synthesis of cartilage-specific matrix components [60]. In summary, obesity contributes to OA through a combination of increased mechanical loading, altered musculoskeletal biomechanics, and systemic inflammatory and adipokine-mediated effects. Notably, although obesity frequently coexists with dyslipidemia, their contributions to OA are not identical. This distinction highlights the need to further differentiate their respective pathogenic roles, as discussed in the following section. The impact of dyslipidemia on OA Dyslipidemia, characterized by reduced high-density lipoprotein (HDL) and elevated levels of cholesterol, triglycerides (TG), oxidized low-density lipoprotein (ox-LDL), and free fatty acids (FFAs), is a common component of the geriatric comorbidity network and plays a critical role in systemic metabolic dysfunction [61]. Beyond its well-established contribution to cardiovascular disease, increasing evidence indicates that dyslipidemia is also closely associated with the development and progression of osteoarthritis (OA) [[62], [63], [64]], even in non-weight-bearing joints [62]. Mechanistically, unlike obesity, which contributes to OA through both mechanical loading and metabolic factors, dyslipidemia acts predominantly through systemic metabolic pathways largely independent of biomechanical stress. It promotes OA primarily via lipid dysregulation and lipotoxicity, whereby circulating lipids disrupt joint homeostasis through oxidative stress, inflammation, and metabolic reprogramming. Epidemiological studies have also reported a positive correlation between hypercholesterolemia and knee pain in the OA group among the elderly, independent of body mass index (BMI) and other metabolic diseases, suggesting that cholesterol may be a systemic risk factor for OA [65]. Additionally, a prospective cohort study has shown that total cholesterol and triglycerides are associated with the incidence of bone marrow lesions in middle-aged women without OA symptoms over a two-year period. Animal experiments have demonstrated that hypercholesterolemia induces OA-like changes, characterized by proteoglycan loss, collagen and aggregated proteoglycan degradation, osteophyte formation, changes in subchondral bone structure, and cartilage degeneration, highlighting the role of cholesterol in OA pathogenesis [66]. Research has also shown that OA patients exhibit a decrease in the expression of genes associated with cholesterol efflux in joint cartilage, leading to cholesterol deposition within chondrocytes [67]. Several studies have found that cholesterol accumulation in chondrocytes triggers a series of downstream adverse responses, including mitochondrial dysfunction, increased reactive oxygen species (ROS) production, amplified inflammation, enhanced matrix degradation, and increased chondrocyte apoptosis, thereby exacerbating the progression of OA [[68], [69], [70]]. HDL is considered to have anti-inflammatory and antioxidant properties. It can clear excess cholesterol through reverse cholesterol transport, reducing lipid accumulation in cells and counteracting oxidative stress. A retrospective clinical study showed that OA patients had elevated serum total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels, whereas HDL-C and ApoA1 levels were reduced. HDL-C and ApoA1 levels in synovial fluid were negatively correlated with cartilage damage, radiological severity, and the severity of primary knee OA symptoms, suggesting that they could serve as potential predictors of OA severity [71]. Similarly, low HDL-C levels have been identified as a risk factor for increased OA symptoms [72]. However, a recent study proposed an opposing view regarding the role of HDL-C [73]. Animal studies showed that LCAT−/− and ApoA-1−/− mice, both of which are necessary for the formation of mature HDL-C particles, exhibited significantly lower functional HDL-C levels and showed cartilage fibrosis, vertical fissures, chondrocyte aggregation, and reduced proteoglycan (PG) content, with increased expression of MMP-2, MMP-9, and MMP-13 compared to control mice. These findings suggest that disruptions in HDL metabolism pathways increase the risk of OA in mice. The role of LDL, especially oxidized LDL (ox-LDL), in OA has received increasing support from evidence. Ox-LDL is believed to play a central role in the pathophysiology of OA. First, ox-LDL may activate synovial cells, particularly macrophages, endothelial cells, and synovial fibroblasts, which could induce large amounts of pro-inflammatory factors and cytokines. These factors include growth factors (e.g., TGF-β), matrix metalloproteinases (MMPs, especially MMP-1 and MMP-3), cytokines (e.g., IL-6, IL-8, TNF-α), and chemokines (e.g., MCP-1), all of which exacerbate local inflammation [74]. After macrophage activation, in addition to secreting these pro-inflammatory factors, it increases the uptake of ox-LDL, promoting ROS production and intensifying inflammation. Activation of endothelial cells also increases the expression of leukocyte adhesion molecules, promoting monocyte migration and enhancing local immune responses [75]. Moreover, ox-LDL accumulation not only triggers inflammation in the synovium but also affects chondrocytes. Studies have shown that ox-LDL may induce ROS production in chondrocytes via specific receptors (e.g., LOX-1, ox-LDL receptor), and ROS accumulation leads to chondrocyte apoptosis or hyperproliferation, thereby disrupting the normal cartilage matrix [76]. Ox-LDL also promotes the synthesis and secretion of MMP-3, enhancing matrix degradation and providing a basis for cartilage destruction [77]. Additionally, ox-LDL activates transcription factors (e.g., Runx2), inducing chondrocytes to exhibit a phenotype similar to ossification, resulting in the production of high levels of type X collagen in cartilage, further accelerating cartilage degeneration [78]. These findings emphasize the significant role of hypercholesterolemia and ox-LDL in initiating and advancing OA, as they possess the inherent ability to disrupt joint tissue homeostasis and induce inflammation and cartilage degradation. Systemic FFA elevation is also a characteristic of lipid metabolism abnormalities. FFA activates Toll-like receptors (TLRs) on synovial cells, activating signaling pathways such as TAK1, JNK, p-38, c-Jun, and NF-κB, inducing inflammatory responses and promoting the production of cytokines, iNOS, and COX-2, thereby intensifying local inflammation [79]. Furthermore, saturated fatty acids (SFA), such as palmitic acid and stearic acid, promote cartilage matrix remodeling by activating autophagy and modulating the NFκB signaling pathway, leading to cartilage damage [80]. FFA also accelerates cartilage degeneration by altering chondrocyte metabolism, increasing endoplasmic reticulum stress (UPR), and inducing cell apoptosis [81]. Beyond these immediate cytotoxic effects, emerging evidence underscores that the joint microenvironment undergoes a profound metabolic and age-related transformation. On one hand, senescent cells within the joint can “recycle” intracellular lipids from droplets to sustain their pro-inflammatory senescence-associated secretory phenotype (SASP), effectively linking aging biology to systemic lipid dysregulation [82]. On the other hand, intra-articular lipid accumulation is activey driven by the CircRREB1-FASN axis, which accelerates lipid synthesis and further reinforces lipid-related senescent phenotypes in chondrocytes [83]. These multi-layered metabolic disturbances converge on a fundamental reprogramming of chondrocyte homeostasis. Specifically, excessive FFA accumulation forces a shift toward enhanced fatty acid oxidation (FAO), leading to the pathological accumulation of intracellular acetyl-CoA [84]. The accumulation of FFAs triggers metabolic lipotoxicity by increasing acetyl-CoA levels, which alters the epigenetic landscape of chondrocytes through protein acetylation. The resulting loss of SOX9-mediated anabolic activity, coupled with a compensatory increase in matrix-degrading enzymes (e.g., MMPs and ADAMTS), shifts chondrocyte identity toward a persistent catabolic state [84]. This metabolic–epigenetic axis represents a key mechanism by which dyslipidemia promotes OA pathogenesis, providing a pathological basis that is considerably more complex than the mechanical damage associated with simple obesity. Taken together, dyslipidemia drives OA progression through a complex network of lipid-induced cellular toxicity, oxidative stress, and metabolic reprogramming. These processes fundamentally alter chondrocyte homeostasis, promote a persistent catabolic phenotype, and accelerate joint degeneration. This lipotoxic mechanism highlights the critical role of systemic metabolic dysfunction in OA and provides a distinct pathological basis for targeting lipid metabolism in disease management. The impact of diabetes on OA Diabetes is one of the most common chronic diseases in the elderly, and its impact on OA has become an increasingly important health issue. Although obesity is often a shared risk factor for both type 2 diabetes mellitus (T2DM) and OA, more and more studies indicate that T2DM itself may be an important independent factor for OA, promoting its onset and progression through various mechanisms, rather than just through increased weight burden [[85], [86], [87]]. First, hyperglycemia is one of the hallmarks of T2DM, and its impact on articular cartilage, synovium, and subchondral bone is one of the key factors driving the development of OA. Studies show that high blood glucose may directly affect the metabolism of chondrocytes, leading to cell death and cartilage degeneration. The high glucose state promotes the production of ROS, enhances oxidative stress, and directly damages the structure and function of chondrocytes [88]. Additionally, high glucose concentrations can inhibit the chondrogenic differentiation of mesenchymal stem cells, thereby reducing cartilage regeneration ability [89]. Moreover, a high-glucose environment is closely associated with the accumulation of advanced glycation end-products (AGEs), which are recognized by pattern recognition receptors (PRRs) expressed on chondrocytes, such as the receptor for advanced glycation end-products (RAGE) and TLR-4. These receptors trigger downstream signaling pathways, including the MAP kinase and NF-κB pathways, leading to a pro-inflammatory and catabolic state in chondrocytes [90]. These mechanisms are closely related to the glucose metabolism regulation in chondrocytes. Normal chondrocytes can sense changes in extracellular glucose levels, maintaining homeostasis by regulating GLUT-1 synthesis and its lysosome-mediated degradation. However, OA chondrocytes have defects in this regulation, unable to adapt to increased extracellular glucose concentrations, leading to glucose accumulation, which exacerbates ROS production, AGEs accumulation, and inflammation [88,91]. AGEs could potentially suppress the AMPKα/SIRT1/PGC-1α signaling in chondrocytes, which may subsequently trigger mitochondrial dysfunction due to increased oxidative stress, inflammation, and apoptosis [92]. Additionally, the accumulation of AGEs not only alters the biomechanical properties of cartilage, making it more fragile, but also increases cartilage sensitivity to mechanical stress, further accelerating cartilage degeneration [93]. Activating autophagy can alleviate diabetes-induced chondrocyte damage, thus slowing the progression of OA [94]. Secondly, another important mechanism of T2DM is insulin resistance. Insulin resistance not only affects systemic metabolism but also plays a crucial role in local joint tissues. Under normal conditions, insulin regulates the metabolism of chondrocytes through its receptor, promoting the synthesis of cartilage matrix [95]. However, in T2DM patients, the function of the insulin receptor is suppressed, preventing insulin from effectively activating its receptor, thus losing its protective effect on articular cartilage [96]. Moreover, insulin resistance leads to elevated blood glucose levels and increased concentrations of free fatty acids (FFAs) in serum, which can accelerate the progression of OA [97]. In addition, the synovium in T2DM patients exhibits significant differences in inflammation and immune responses compared to healthy individuals. Studies show that T2DM patients have an increased number of macrophages in the synovium, with significantly elevated expressions of inflammatory factors like TNF-α. These changes exacerbate synovial inflammation and accelerate the progression of OA [98], which is consistent with clinical observations [99,100]. The formation of new blood vessels in the synovium and the release of cytokines, particularly pro-inflammatory cytokines, are more pronounced in T2DM patients, which not only accelerates cartilage degradation but also contributes to the loss of joint function [101]. Apart from these mechanisms, the metabolic dysregulation in T2DM may also trigger microvascular changes, further impacting OA. Studies have shown that microvascular changes caused by diabetes increase the risk of certain joint diseases, such as shoulder inflammatory arthritis, Dupuytren's contracture, shoulder-hand syndrome, and Charcot's joint, which typically affect the lower limbs, such as the ankle and foot [102,103]. The same mechanisms may also occur in the relationship between diabetes and OA. It is well known that the subchondral regions of long bones are highly vascularized, indicating a high demand for nutrients in these areas [104]. Since diabetes can cause significant microvascular changes, it may increase the risk of OA through this pathway, but more evidence is needed to confirm this. The impact of hypertension on OA Hypertension is a common chronic disease among the elderly, not only an independent risk factor for cardiovascular and cerebrovascular diseases [105], but also playing a key role in the pathogenesis and progression of OA, with a significant impact on joint health in elderly patients [106,107]. A large number of epidemiological studies have established a close association between hypertension and OA. The Framingham OA study showed that after adjusting for factors such as BMI and age, the risk of knee OA in hypertensive patients was still 1.45 times higher (95% CI: 1.12–1.88), and those with systolic blood pressure >112 mmHg and pulse pressure >39 mmHg had a significantly higher incidence of radiographic OA [108]. A systematic review incorporating 26 studies with 97,960 participants revealed that hypertensive patients exhibit significantly higher overall risks of developing osteoarthritis compared to individuals with normal blood pressure, with distinct regional variations: the condition shows strongest association with knee osteoarthritis and no significant link to hand osteoarthritis, suggesting that weight-bearing joints are more susceptible to hypertension-related pathological factors [107]. Subgroup analyses further demonstrated that hypertension demonstrated significantly stronger correlation with radiographic knee osteoarthritis (characterized by cartilage defects and osteophyte formation) than symptomatic knee osteoarthritis (primarily manifested by joint pain), indicating that hypertension may cause structural damage to osteoarthritis rather than mere pain. Notably, this association remained independent of body mass index (BMI) — even after adjusting for BMI, the link between hypertension and radiographic knee osteoarthritis persisted, ruling out obesity as the sole mediating factor. Gender differences were particularly pronounced, with female hypertensive patients showing significantly higher risks of radiographic knee osteoarthritis than males, potentially linked to genetic factors such as female hormone levels and angiotensin-converting enzyme (ACE) gene polymorphisms (more prevalent in Asian populations) [106,107]. The impact of hypertension on osteoarthritis (OA) is first reflected in local vascular dysfunction within the joint. In the subchondral bone, hypertension may increase intraosseous pressure (positively correlated with systolic blood pressure and pulse pressure), reducing arterial inflow and venous outflow, thereby causing insufficient perfusion [109,110]. Dynamic contrast-enhanced MRI shows that the clearance of contrast agent in the subchondral bone of patients with knee OA is slow, indicating impaired venous outflow, while reduced arterial inflow further exacerbates intraosseous ischemia [111]. In the ischemic state, the apoptosis rate of osteocytes increases, releasing receptor activator of nuclear factor-κB ligand (RANKL), which activates osteoclast-mediated bone resorption, forming bone cysts and weakening the supportive structure of cartilage [112,113]. Meanwhile, hypoxia may induce chondrocytes to upregulate glucose transporter 1 (GLUT1); although this accelerates glucose uptake, it shifts metabolism toward anaerobic glycolysis, leading to lactic acid accumulation, acidification of the cartilage matrix, and inhibition of type II collagen and proteoglycan synthesis [[114], [115], [116]]. In synovial tissue, hypertension also stimulates the secretion of vascular endothelial growth factor (VEGF), promoting synovial microvascular proliferation and increased vascular permeability, while reducing lymphatic vessel density [[117], [118], [119]]. This leads to joint effusion and retention of inflammatory factors (IL-6, TNF-α), further exacerbating synovitis and cartilage degradation. Beyond the direct disruption of local vascular function, the pathological association between hypertension and OA is further reinforced by the abnormal activation of multiple shared molecular pathways, among which the renin-angiotensin system (RAS), endothelin system, and Wnt/β-catenin pathway are the most critical. In the context of hypertension, the RAS is activated both systemically and locally within the joint. Angiotensin II (Ang II) promotes chondrocyte hypertrophy via its type 1 receptor (AT1), upregulates catabolic genes such as RUNX2 and MMP-13, and simultaneously induces synovial fibroblasts to secrete IL-1β, accelerating the degradation of the cartilage matrix [120,121]. Endothelin 1 (ET1), a potent vasoconstrictor, is significantly elevated in the synovial fluid of both hypertensive patients and OA patients [122,123]. By activating the endothelin type A receptor (ETAR), it triggers a positive feedback loop of reactive oxygen species (ROS) production, promoting the expression of MMP-1 and MMP-13 as well as synovial thickening [123,124]. Furthermore, ET1 may inhibit Dickkopf 1 (DKK1), an antagonist of the Wnt pathway, leading to excessive activation of the Wnt/β-catenin pathway. This not only inhibits the expression of Sox9 in chondrocytes (a key factor for chondrocyte differentiation) but also promotes abnormal osteogenesis and bone sclerosis in the subchondral bone [125]. The abnormal activation of molecular pathways ultimately affects the core functional structure of the joint—the subchondral bone-cartilage functional unit—leading to the disruption of its homeostasis. In the early stages of OA, hypertension-related increased intraosseous pressure and ischemia lead to trabecular bone resorption and thinning of the cortical bone in the subchondral region; in the late stages, due to imbalanced bone remodeling, bone sclerosis occurs alongside impaired mineralization (associated with upregulated DKK2 inhibiting Wnt-mediated mineralization) [106]. This structural abnormality disrupts mechanical conduction and nutrient exchange between bone and cartilage. Increased microcracks in the cement line facilitate the invasion of subchondral bone blood vessels into the calcified cartilage layer, which release bone-derived catabolic factors (e.g., 14-3-3ε protein), inducing phenotypic changes in chondrocytes and matrix degradation [126]. At the same time, the incidence of hypertension-related bone marrow lesions (BMLs) increases. The BML regions exhibit vascular proliferation but poor perfusion, which not only serves as an important source of pain but also accelerates cartilage erosion by releasing inflammatory factors [127,128]. In conclusion, the impact of hypertension on osteoarthritis (OA) in elderly populations cannot be underestimated. By inducing pathological changes in local joint blood vessels such as subchondral bone ischemia, combined with abnormal activation of molecular pathways including the renin-angiotensin system, endothelin system, and Wnt/β-catenin pathway, hypertension disrupts the homeostasis of subchondral bone-cartilage functional units. This disruption, coupled with genetic factors and altered joint biomechanical environments, collectively drives the onset and progression of OA. A thorough understanding of these pathological mechanisms is crucial for developing targeted intervention strategies and improving outcomes for elderly OA patients. Future research should further focus on this interdisciplinary field to provide theoretical support for exploring effective OA prevention and treatment measures. The impact of sarcopenia on OA Sarcopenia refers to the gradual decline in skeletal muscle mass and strength with age, commonly observed in the elderly population. It is characterized not only by muscle loss but also by a decrease in muscle strength and function, leading to reduced mobility, increased fall risk, and a lower quality of life in the elderly [129,130]. Recent studies have suggested that sarcopenia may be one of the significant causes of the onset and progression of OA. Sarcopenic individuals often experience a reduction in lower limb muscle mass, especially weakness in the quadriceps, which increases the burden on the joints, particularly weight-bearing joints like the knees, thereby accelerating the onset and development of OA. Studies have shown that the reduction in lower limb muscle mass, especially the decline in quadriceps strength, is an independent risk factor for the onset of knee OA [131,132]. Additionally, sarcopenia may lead to increased pain severity and accelerated joint damage in knee OA patients [133]. A study by ALGHADIR et al. [134] found that enhancing muscle strength, particularly through exercises targeting the quadriceps, can improve joint function, alleviate pain, and reduce functional impairments in knee OA patients, thereby improving their quality of life. As muscle strength and mass decline, the biomechanical structure of the joint changes, leading to reduced joint stability and accelerating cartilage degeneration. Research has found that sarcopenic KOA (knee OA) patients experience more severe pain and worse quality of life than non-sarcopenic patients. Reid et al. [135] in a randomized controlled trial found that muscle strength is an independent predictor of pain and quality of life in KOA patients, which aligns with the results of Kim et al. [136] based on a cross-sectional survey of 5723 individuals. A longitudinal study by Gao et al. [134] on 6212 individuals aged ≥60 years also concluded similarly. Moreover, sarcopenia decreases pain tolerance [131]. Andrews et al. [137,138] found that KOA patients with reduced total limb muscle mass experience more severe knee pain. Therefore, sarcopenia can both induce KOA and accelerate its progression, as well as exacerbate pain in KOA patients. Additionally, genetic evidence suggests that in the European population, a decline in limb muscle mass, grip strength, and walking speed increases the risk of KOA, while a reduction in limb muscle mass increases the risk of hip OA in sarcopenic patients [139]. Animal studies have shown that muscle atrophy may contribute to abnormal changes in subchondral bone and cartilage degeneration in rats [140]. In rabbit models of muscle atrophy, similar cartilage degeneration was observed, along with an increase in inflammatory cells within the joints [141]. These findings suggest that sarcopenia contributes to OA onset and progression by altering joint load, intensifying inflammatory responses, and weakening joint stability. However, the exact mechanisms through which sarcopenia leads to OA require further investigation to fully uncover the pathways and potential targets involved. The impact of other geriatric comorbidities on OA In addition to the geriatric comorbidities discussed above, studies have shown that in 11-month-old OA rats, Alzheimer's disease (AD) pathology induced by hippocampal Aβ injection significantly exacerbates cartilage degeneration and accelerates clinical symptoms of OA, such as joint swelling, limping, reduced running speed, uneven weight distribution on the legs, and increased inflammation and pain [142]. Another study indicated that depression might exacerbate OA symptoms by promoting weight gain, reducing physical activity, and inducing inflammation. Specifically, depression increases pro-inflammatory cytokines (such as IL-6 and TNF-α) and alters neuroendocrine functions, further intensifying inflammation and progression of OA [143]. Furthermore, Mendelian randomization analysis has confirmed a genetic link between depression and OA, suggesting that genetic susceptibility to depression may increase the risk of OA [144,145]. Therefore, managing AD and depression can not only alleviate their symptoms but may also improve symptoms in OA patients, enhancing their quality of life. Additionally, research has shown that OA comorbidity is more common in elderly patients with chronic obstructive pulmonary disease (COPD) [146]. However, COPD is not a causative factor for OA, and vice versa. The association between the two conditions may arise from shared risk factors, such as age, obesity, prolonged low physical activity, and chronic inflammation [147]. Previous studies have shown that diseases within the geriatric comorbidity network do not act independently on OA; instead, they exert a synergistic regulatory effect through multidimensional mechanisms, including mechanical stress, metabolic disturbances, and inflammation. As illustrated in Fig. 2, it presents the panoramic mechanism by which geriatric comorbidities drive the pathological progression of OA, providing visual reference for understanding the “regulated role” of OA in the comorbidity network. Schematic diagram of the mechanisms by which geriatric comorbidities impact OA. OA and its impact on geriatric comorbidities The impact of OA on osteoporosis As mentioned earlier, the inflammatory state in osteoporosis can affect the onset and progression of OA. Similarly, in OA patients, there is also localized joint inflammation, which releases inflammatory factors such as IL-1, IL-6, and TNF-α. Theoretically, these inflammatory factors may stimulate osteoclasts, enhancing their activity and promoting bone resorption. At the same time, these factors suppress osteoblast differentiation, reducing bone formation, which leads to gradual bone loss and an increased risk of developing osteoporosis [148,149]. In addition, the regulation of bone resorption involves the receptor activator of nuclear factor kappa-B ligand (RANKL) and osteoprotegerin (OPG) system. RANKL binds to its receptor RANK to promote the formation and activation of osteoclasts, whereas OPG inhibits this process by binding to RANKL and preventing its interaction with RANK, thereby inhibiting osteoclast activity [[150], [151], [152]]. In OA, inflammatory factors may upregulate the expression of RANKL, thus promote osteoclast activity and further accelerating bone resorption [153,154]. However, further research is needed to confirm these findings, though recent studies provide supporting evidence for this bidirectional interplay. Besides inflammatory factors, the impact of OA on osteoporosis is closely related to changes in mechanical stress. Due to joint pain, swelling, and stiffness caused by OA, patients experience restricted joint mobility and reduced physical activity, which results in a significant reduction in the stress exerted on the bones. According to Wolff's law, bones remodel in response to stress stimuli, so a reduction in stress leads to decreased osteoblast activity, reduced bone formation, and a relative increase in osteoclast activity, thus accelerating bone resorption [155]. Over time, this change may lead to bone loss, eventually resulting in osteoporosis. Furthermore, OA causes cartilage wear and damage, leading to uneven distribution of force on the subchondral bone. Excessive pressure on local bone tissue overactivates osteoclasts, accelerating bone resorption, while insufficient pressure on other areas reduces osteoblast activity, decreasing bone formation [126,156,157]. This uneven bone metabolism further promotes the development of osteoporosis. The impact of OA on neurodegenerative diseases AD is a common neurodegenerative disorder, primarily characterized by progressive memory loss, cognitive decline, and behavioral changes, and it is the most common form of dementia in the elderly. A growing body of evidence points to a bone-brain cross-talk mechanism—an interaction between the skeletal system and the brain—as a potential biological basis for the observed association between OA and AD risk [[158], [159], [160]]. Clinical studies have shown that among cognitively normal elderly individuals, those with OA exhibit significantly greater hippocampal atrophy than those without OA, suggesting that OA may increase the risk of AD [161]. OA patients experience a significant increase in memory impairment and risk of AD, especially in those with pain [162,163]. The more severe the chronic pain caused by OA, the higher the incidence of AD [164]. Research has reported that chronic pain caused by OA is associated with impairments in various cognitive domains, including memory, attention, processing speed, and executive function, indicating that chronic pain plays an important role in the impact of OA on AD clinical symptoms [165,166]. Further studies are needed to determine whether OA and its associated pain independently affect AD and to explore more potential mechanisms. A longitudinal study showed that OA patients accumulate β-amyloid (Aβ) more quickly, and Aβ-associated tau protein deposition in the motor cortex and somatosensory cortex is significantly increased, particularly in individuals carrying the APOE-ε4 gene. This suggests that OA may accelerate the accumulation of these key pathological features, thereby increasing the risk of AD [167]. Additionally, the systemic chronic inflammation caused by OA may contribute to the development and progression of AD. In AD, the blood-brain barrier function is impaired, leading to increased permeability, allowing peripheral inflammatory factors to enter the brain, triggering neuroinflammatory responses, neuronal damage, and neurodegeneration, thus accelerating the progression of AD [168]. In basic research, knee OA-induced inflammatory cytokines (e.g., IL-1β and TNF-α) increase, leading to low-grade systemic chronic inflammation, which further causes neuroinflammation, accelerates Aβ deposition, and promotes neurodegenerative changes in the brain, driving the pathological progression of AD [169,170]. Although a previous Mendelian randomization study in a European population showed no causal relationship between OA and AD, increasing basic and clinical studies have found that OA may promote the onset and progression of AD [171,172]. Therefore, more research is needed to clarify the causal relationship between OA and AD. The impact of OA on cardiovascular disease Cardiovascular disease (CVD), as the leading global health killer, has a profound impact. It accounts for half of global deaths from non-communicable diseases and is the primary cause of death in China, making up more than 40% of the total mortality. Notably, there seems to be a hidden connection between OA and cardiovascular diseases. Several clinical studies from different countries have found that OA patients have a higher risk of CVD [[173], [174], [175], [176], [177]]. Meta-analytic studies also indicate that OA is an important risk factor for CVD [178,179]. A study on the relationship between hand OA (HOA) and subclinical cardiovascular disease (sCVD) in middle-aged women showed that women with HOA had a 36% higher likelihood of carotid atherosclerosis compared to those without the condition [180]. Notably, the association between OA and cardiovascular disease remained even after controlling for traditional cardiovascular risk factors (such as obesity, hypertension, diabetes, etc.) [181]. Recent genetic studies using Mendelian randomization have explored potential causal associations between OA and CVD at the genetic level. The results suggest that OA may increase the incidence of cardiovascular diseases such as stroke, primary hypertension, heart failure, and atrial fibrillation. One of the potential mechanisms underlying this association lies in the significant elevation of inflammatory mediators such as TNF-α and IL-6 in patients with OA. These mediators serve as key linkages driving the development and progression of cardiovascular diseases—through the synergistic effects of impairing the integrity of vascular structures, accelerating the pathological progression of atherosclerosis, and disrupting the balance of the coagulation-fibrinolysis system, they inflict multidimensional damage on the cardiovascular system [181]. Additionally, OA-induced reduced physical activity may increase the likelihood of cardiovascular disease [182,183]. Furthermore, recent large-scale twin studies (n ~ 60,000) indicate that the co-occurrence of OA and severe CVD is largely driven by shared genetic liability (explaining 85% to 100% of the correlation) rather than a simple causal chain. The observed discrepancies in various studies may stem from phenotypic and disease-specific heterogeneity: while the correlation between hip OA and CVD is almost entirely genetically driven, knee OA is more susceptible to unique environmental factors such as mechanical injury. Moreover, while arrhythmias and coronary heart disease show strong genetic sharing with OA, heart failure appears to be mediated more by environmental exposures. These findings suggest a common etiology between the two conditions, highlighting the need for site-specific and disease-specific risk screening in clinical practice to account for population heterogeneity and varying pathological phenotypes [184]. The impact of OA on depression and anxiety Depression and anxiety are common mental health issues in the elderly, especially among those with multiple chronic diseases. The incidence of depression and anxiety is higher in this group and is closely related to disease progression and a decline in quality of life. Chronic pain caused by OA is considered a significant factor contributing to depression and anxiety [17,185]. Studies show that OA patients are more likely to experience depression and anxiety symptoms than the healthy population, with this association being particularly pronounced in those with severe pain [[186], [187], [188]]. Chronic pain not only affects physical function but also may lead patients to feel helpless, lonely, and hopeless, which can trigger or exacerbate depression. The continuous presence of pain is closely related to the brain's emotional regulation mechanisms. Chronic pain may affect the balance of neurotransmitters and alter areas in the brain associated with emotion and stress responses, such as the prefrontal cortex and hippocampus, thereby increasing the incidence of depression and anxiety [165]. Additionally, the functional limitations and reduced social activity in OA patients are significant factors in the development of depression. OA patients often reduce daily activities due to pain, and the resulting feelings of social isolation and loneliness are important contributors to the development of depression and anxiety [189]. Some studies have also pointed out that the chronic pain in OA and the demand for pain management may sometimes lead to sleep disturbances, further impacting mental health and quality of life. Sleep disruption can lead to increased irritability, cognitive decline, and intensification of anxiety and depression [190]. In terms of biological mechanisms, chronic inflammation caused by OA may play an important role in the onset of depression. Studies have found that inflammatory factors (e.g., TNF-α, IL-6) are elevated in OA patients. These inflammatory factors not only affect the joints but may also affect the nervous system, particularly by crossing the blood-brain barrier and inducing neuroinflammation, which is closely related to the development of depression and anxiety [[191], [192], [193], [194]]. Chronic low-grade inflammation has a significant biological link to depression, as inflammatory factors play a crucial role in regulating brain function, mood, and behavior [195]. The impact of OA on sarcopenia As mentioned earlier, sarcopenia can act as an independent influencing factor in the onset and progression of OA. However, OA itself also promotes the onset and development of sarcopenia. A study by Aslan et al. [196] found that malnutrition and vitamin D deficiency in patients with knee OA (KOA) increase the incidence of sarcopenia in these patients. Furthermore, a large cross-sectional study in Germany revealed that women over the age of 70 who suffer from hip or knee OA have a significantly higher prevalence of sarcopenia [197]. This finding suggests a close relationship between KOA and sarcopenia, with KOA potentially accelerating the progression of sarcopenia. Further studies have shown that the muscle tissue in KOA patients differs in some physiological characteristics compared to healthy individuals. Research found that KOA patients have higher levels of type IIa/x fibers and extracellular matrix in their muscles, while the satellite cell density is significantly lower than in healthy individuals [198]. The transformation of type I muscle fibers into type IIa/x fibers indicates a decline in muscle strength and mass. As KOA progresses, the proportion of type IIa/x fibers in the vastus lateralis muscle of KOA patients gradually increases, which leads to the onset of sarcopenia [198]. An increase in the extracellular matrix of skeletal muscle reduces muscle strength, and satellite cells play a key role in promoting muscle repair and regeneration [199], as well as in reducing extracellular matrix [200]. Tsukada et al. [201] used bilateral CT analysis to assess the muscle volume of KOA patients and found a significant reduction in the volume of muscles around the knee joint in KOA patients. Cunha et al. [202] found that in KOA model rats, the quadriceps and tibialis anterior muscles atrophied, accompanied by neuromuscular junction remodeling, further revealing the impact of KOA on muscle tissue structure and function. The most recent study, through histopathological analysis of the quadriceps muscles around the OA-affected joints, revealed that chronic inflammation is a core pathological feature, accompanied by infiltration of macrophages with a senescent phenotype. The study found that these senescent macrophages exacerbate muscle atrophy by inducing skeletal muscle ferroptosis. The molecular mechanism for this is the inhibition of the asparagine-mTORC1-HMGCR pathway, which leads to reduced endogenous coenzyme Q10 (CoQ10) synthesis, thereby weakening the ferroptosis defense system in skeletal muscle cells. Notably, exogenous supplementation of CoQ10 significantly enhances quadriceps mass and improves the pathological damage of OA joints [203]. Therefore, not only can sarcopenia lead to the onset and progression of OA, but OA also acts as an important risk factor for sarcopenia by altering the structure, function, and repair capabilities of muscles. More research is needed in the future to explore the interaction mechanisms between these two conditions. In summary, OA is not merely passively regulated within the geriatric comorbidity network; its inherent pathological characteristics (e.g., chronic inflammation, pain, and limited mobility) can reciprocally reshape the comorbidity landscape (Fig. 3). OA, as a “regulatory source” on the geriatric comorbidity network, offers mechanistic-level visual evidence for the subsequent development of comprehensive intervention strategies for patients with comorbidities. Schematic diagram of the reverse regulatory effects of OA on geriatric comorbidities. Potential drug therapies for comorbidities and their impact on OA While traditional OA treatments primarily focus on alleviating joint symptoms, such approaches are often insufficient to address the complex, multisystem nature of OA in elderly patients with comorbidities. Increasing evidence suggests that many drugs originally developed for chronic diseases—including osteoporosis, diabetes, cardiovascular disease, and obesity—may exert disease-modifying effects on OA by targeting shared pathological pathways. These shared mechanisms include dysregulated bone remodeling, chronic low-grade inflammation, metabolic imbalance, and impaired cellular homeostasis. Therefore, rather than acting as isolated interventions, these drugs can be conceptually integrated into a unified therapeutic framework that targets the common biological basis linking OA and geriatric comorbidities. In this section, we summarize representative pharmacological agents according to their primary mechanisms of action and discuss their potential roles in modulating OA progression within this integrated, comorbidity-oriented framework (Table 1). Table 1Potential efficacy and research progress of different drug classes in osteoarthritis (OA).Table 1Drug ClassRepresentative DrugsOriginal IndicationsPossible Mechanisms of ActionResearch Evidence on OACurrent Research StageRecommendation for OA TreatmentAnti-Osteoporosis DrugsBisphosphonatesOsteoporosisInhibit osteoclast activity, reduce bone resorption, protect subchondral bone, slow cartilage degenerationAnimal studies and some clinical research show that bisphosphonates improve subchondral bone density, slow cartilage degeneration, and reduce joint painClinical research+ animal studiesPotential, needs more clinical data supportAnti-Osteoporosis DrugsVitamin DOsteoporosisRegulate calcium and phosphorus metabolism, inhibit inflammation, activate autophagy, improve cartilage repairMultiple clinical and animal studies show that vitamin D supplementation helps slow cartilage degeneration, improve joint function, and reduce pain, especially in patients with low vitamin D levelsClinical research+ animal studiesRecommended for knee OA treatmentAnti-Osteoporosis DrugsCalcitoninOsteoporosisInhibit osteoclast activity, reduce bone resorption, protect subchondral bone, promote cartilage repairPreclinical and clinical studies show that calcitonin inhibits bone resorption, protects subchondral bone, slows cartilage degeneration, and has anti-inflammatory and antioxidant effects, reducing pain and improving functionClinical research+ animal studiesPotential, needs more clinical data supportAnti-Metabolic DrugsMetforminType 2 DiabetesActivate AMPK, anti-inflammatory, antioxidant, autophagy activation, anti-cell agingAnimal models and retrospective clinical studies show it can slow cartilage degeneration and relieve painClinical observation+ mechanism researchPotential, needs more RCT supportIncretin DrugsGLP-1 Receptor Agonists (e.g., Liraglutide)Type 2 DiabetesAnti-inflammatory, reduce chondrocyte apoptosis, regulate metabolismInitial animal model studies support efficacyClinical research+ animal studiesPotential drug, requires clinical validationLipid-regulating DrugsStatins (e.g., Atorvastatin)Hyperlipidemia, cardiovascular diseaseAnti-inflammatory, inhibit NF-κB, improve vascular functionObservational studies suggest they may slow OA progression; clear supporting mechanismsExtensive epidemiological data+ some mechanism studiesControversial, not recommended for routine useAntidepressantsSNRI (e.g., Duloxetine)Depression, chronic painRegulate neuroinflammation and central sensitizationFDA approved for OA pain managementApplied in OARecommended for OA patients with pain Potential efficacy and research progress of different drug classes in osteoarthritis (OA). Bisphosphonates As a first-line treatment for osteoporosis, bisphosphonates (BPs) primarily reduce bone resorption by inhibiting osteoclast activity. Within the geriatric comorbidity network, the clinical value of BPs extends beyond maintaining systemic bone mineral density; it lies in their potential to synergistically treat both osteoporosis and OA by intervening in the “bone-cartilage crosstalk," a shared pathological pathway [[204], [205], [206]]. During OA progression, aberrant remodeling and hypermineralization of the subchondral bone increase its stiffness, leading to abnormal mechanotransduction that accelerates the wear of the overlying articular cartilage. By regulating the balance of bone metabolism, BPs effectively stabilize the subchondral bone microstructure and reduce the release of degradation enzymes, such as matrix metalloproteinases (MMPs), triggered by high bone turnover. This indirectly preserves the integrity of the cartilaginous matrix [207,208]. Furthermore, animal models and clinical data have demonstrated that BPs can alleviate joint pain while improving biochemical markers of bone turnover in OA patients [[208], [209], [210], [211], [212]]. However, the clinical efficacy of BPs for OA remains controversial across different studies [[213], [214], [215]]. This inconsistency likely stems from the heterogeneity of OA pathological phenotypes: BPs may yield significant benefits only in patients exhibiting a “high bone turnover phenotype," while having limited effects on phenotypes dominated by inflammation or metabolic dysfunction. Therefore, incorporating BPs into an integrated treatment strategy for OA requires precise stratification based on the patient's bone metabolic status. Therefore, the therapeutic efficacy of BPs in OA may depend on the underlying bone metabolic status, highlighting the importance of phenotype-specific treatment strategies in patients with OA and osteoporosis. Vitamin D Vitamin D is a critical regulator of systemic calcium-phosphate metabolism and bone homeostasis, serving as a vital link in the geriatric comorbidity network [216]. Beyond its established role in preventing osteoporosis, Vitamin D exerts protective effects on the OA joint environment by targeting two common pathological pathways discussed earlier: chronic inflammation and impaired cellular homeostasis [217,218]. Through its receptor (VDR), Vitamin D acts as an immunomodulator that inhibits the NF-κB pathway, thereby suppressing the systemic and local release of pro-inflammatory cytokines such as TNF-α and IL-1β [219,220]. Simultaneously, Vitamin D reinforces the “organ-crosstalk” defense by activating the AMPK/mTOR signaling pathway to restore autophagic flux in chondrocytes. This enhancement of autophagy, marked by increased LC3 and Beclin-1 expression, allows cells to clear metabolic waste and delay apoptosis, directly addressing the age-related cellular stress that drives both OA and metabolic comorbidities [221,222]. Clinical evidence underscores this integration, as low Vitamin D levels frequently correlate with heightened systemic inflammation and accelerated cartilage loss in OA patients [223,224]. While some clinical trials demonstrate that supplementation can stabilize synovial inflammation and alleviate joint pain, the therapeutic impact is most pronounced when addressed as part of an integrated strategy to manage bone turnover and systemic inflammatory tone [220,[225], [226], [227], [228]]. Consequently, Vitamin D remains a cornerstone of comorbidity-oriented therapy, targeting the metabolic and autophagic deficiencies common to the aging skeleton. Calcitonin Calcitonin (CT), a thyroid-derived peptide hormone traditionally used for osteoporosis, offers a dual-targeting therapeutic potential within the OA-comorbidity network by simultaneously addressing subchondral bone remodeling and joint-specific inflammation [229,230]. Rather than acting solely as an anti-resorptive agent, CT serves as a molecular bridge in the “bone-cartilage crosstalk." By binding to calcitonin receptors (CTR) on both osteoclasts and chondrocytes, it stabilizes the subchondral bone density while concurrently activating the cAMP/PKA signaling pathway to stimulate the synthesis of type II collagen and proteoglycans [230,231]. Crucially, CT aligns with the “integrated treatment strategy” by targeting the common inflammatory cascade discussed in previous sections. It suppresses the release of systemic and local pro-inflammatory cytokines (e.g., TNF-α, IL-1β) and inhibits matrix metalloproteinases (MMPs), thereby protecting the cartilage matrix from the synergistic damage of mechanical instability and chronic low-grade inflammation [[232], [233], [234]]. Clinical evidence supports this multifaceted role, showing that CT not only alleviates joint pain and stiffness but also modulates joint fluid biomarkers, reflecting a systemic metabolic stabilization [[235], [236], [237]]. Consequently, CT represents a promising intervention that transcends symptom management, targeting the shared metabolic and structural pathways inherent in aging patients with bone and joint comorbidities. Metformin Metformin, the cornerstone of type 2 diabetes (T2DM) management, represents a quintessential example of an integrated treatment strategy due to its ability to modulate energy-sensing and inflammatory pathways common to metabolic disorders and OA [238,239]. The primary mechanism for its pleiotropic effects is the activation of AMP-activated protein kinase (AMPK), a master regulator of cellular homeostasis that is typically downregulated in the aging and osteoarthritic joint. By targeting the AMPK/NF-κB and AMPK/mTOR axes, metformin addresses the “shared pathways” of chronic low-grade inflammation and impaired autophagy. Locally, metformin inhibits the polarization of M1 macrophages in the synovium and enhances the anti-apoptotic capacity of chondrocytes by restoring autophagic flux (regulating proteins such as LC3 and Beclin-1) [[240], [241], [242]]. At the systemic level, metformin exhibits exceptional metabolic regulatory capabilities, mitigating oxidative stress, lipid peroxidation, and ferroptosis induced by obesity or diabetes, thereby blocking the transmission of systemic metabolic abnormalities to the local joint environment [243,244]. Clinical and genetic evidence further substantiate these cross-organ benefits: large-scale cohort studies demonstrate that metformin not only significantly reduces the risk of OA in diabetic populations but also provides substantial structural protection in obese patients, including slowing the loss of cartilage volume and reducing the risk of total knee replacement (TKR) [[245], [246], [247]]. Additionally, its analgesic potential—demonstrated through the upregulation of AMPKα1 expression in dorsal root ganglion (DRG) neurons—establishes it as a comprehensive intervention that combines anti-inflammation, metabolic correction, and symptom relief [248]. Consequently, metformin is more than a hypoglycemic agent; it serves as a vital bridge connecting metabolic health and joint integrity, embodying the essence of geriatric comorbidity-oriented therapy. Statins Statins, a commonly used class of lipid-lowering drugs, have demonstrated significant effects in cardiovascular disease prevention. In recent years, their potential in the treatment of OA has also garnered considerable attention [249]. Their primary mechanism—the inhibition of HMG-CoA reductase—not only lowers systemic cholesterol but also modulates pleiotropic pathways critical to joint health, including inflammation, oxidative stress, and autophagy [250]. Statins may act as a metabolic-inflammatory coupler, addressing the lipotoxicity that drives both vascular calcification and chondrocyte senescence. Locally, they counteract the catabolic cascade by inhibiting the STAT1-caspase-3 and NF-κB signaling pathways, thereby downregulating the expression of matrix metalloproteinases (MMPs) and ADAMTS-5 [28,251,252]. Simultaneously, statins restore impaired autophagic flux—a critical cellular defense mechanism—by modulating the MAPK and PI3K/Akt/mTOR axes, which enhances the expression of LC3-II and Beclin-1 to preserve chondrocyte viability [28,253]. Systemically, statins mitigate the “metabolic OA” phenotype by addressing lipotoxicity. They reduce mitochondrial reactive oxygen species (ROS) production and inhibit NLRP3 inflammasome assembly, effectively blocking the pro-inflammatory relay from systemic lipid disorders to the joint [66,254]. By improving mitochondrial function and reducing cholesterol-induced apoptosis, statins bridge cardiovascular lipid management with joint structural preservation. Recent genetic evidence suggests that statins, through LDL-C reduction regulated by the HMGCR gene, are negatively correlated with the risk of knee and hip OA, indicating their potential role in preventing knee OA [255,256]. Clinical studies have shown that individuals using statins have a 40% lower incidence of clinical OA compared to non-users [211]. Moreover, knee OA patients who use statins exhibit significant advantages in pain relief and functional improvement, with a significantly higher proportion of improvement in VAS scores and clinical symptoms compared to non-users [257,258]. Despite these promising insights, clinical findings remain inconsistent, with some studies reporting negligible or even adverse effects on OA progression [259,260]. These discrepancies may stem from metabolic heterogeneity, as statins likely benefit “metabolic phenotypes” driven by dyslipidemia more than post-traumatic or age-related OA [261,262]. Furthermore, statin diversity plays a role; lipophilic variants (e.g., atorvastatin) possess superior membrane permeability and intra-articular bioavailability compared with hydrophilic ones, leading to stronger inhibition of cartilage-degrading enzymes and inflammatory signaling [263]. Finally, methodological limitations, including reliance on retrospective cohorts and a lack of standardized clinical endpoints, further contribute to conflicting results. Therefore, while statins remain a promising disease-modifying candidate, more stratified clinical trials and long-term follow-up are needed to identify the specific patient phenotypes that would most benefit from this therapy. GLP-1 receptor agonists GLP-1 receptor agonists (GLP-1 RAs), originally designed for the treatment of type 2 diabetes and obesity, have emerged as key candidates for the holistic management of obesity-driven OA by modulating the systemic metabolic environment [264]. Their therapeutic value lies in the ability to simultaneously intervene in the common pathological drivers of obesity, diabetes, and OA—namely, mechanical loading abnormalities, metabolic dysregulation, and inflammation [265,266]. At the systemic level, GLP-1 RAs significantly reduce body weight, which not only directly relieves mechanical pressure on the joints but, more importantly, mitigates the systemic low-grade inflammation induced by obesity. At the local level, these drugs exert protective effects by targeting shared inflammatory and oxidative stress pathways. Research indicates that GLP-1 RAs can activate the AMPK signaling pathway, inducing the polarization of M2 macrophages in the synovium and inhibiting the NF-κB axis, thereby significantly reducing the release of pro-inflammatory cytokines such as TNF-α and IL-6 [[267], [268], [269]]. Furthermore, by enhancing mitochondrial function and reducing the production of reactive oxygen species (ROS), GLP-1 RAs protect chondrocytes from endoplasmic reticulum stress and apoptosis, maintaining the structural integrity of type II collagen and proteoglycans [270,271]. No-tably, recent evidence further indicates that semaglutide can attenuateOA progression through a weight loss-independent metabolic restora-tion mechanism, suggesting that metabolic reprogramming may con-tribute directly to joint protection and further expanding the mechanis-tic understanding of GLP-1 RAs in OA treatmen [272]. Clinical evidence further substantiates these multi-target integrated benefits. The STEP-9 trial and several cohort studies have shown that patients receiving GLP-1 RA treatment not only experience significant relief in joint pain but also have a markedly lower risk of total knee replacement (TKR) [265,266,273]. This systemic-to-local protective paradigm exemplifies how targeting metabolic dysfunction can indirectly preserve joint integrity, reinforcing the concept of OA as a systemic disease in elderly populations. Duloxetine Duloxetine, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), is a first-line treatment for depression, generalized anxiety disorder, and neuropathic pain caused by diabetes [274,275]. In the context of OA management, its clinical significance lies in its dual modulation of central sensitization and local inflammation, effectively targeting the shared neuro-physiological pathways between OA and its psychological or neurological comorbidities [276]. Locally, duloxetine exhibits chondroprotective potential that extends beyond mere symptom relief. It has been shown to suppress the expression of IL-1β and TNF-α while downregulating cartilage-degrading enzymes like MMP-13 and ADAMTS-5, thereby mitigating the systemic low-grade inflammation and chondrocyte apoptosis associated with OA progression [277,278]. Centrally, by enhancing the descending pain inhibitory system, duloxetine blocks the aberrant pain signal transmission characteristic of central sensitization. Clinical evidence substantiates this multidimensional intervention, demonstrating that duloxetine significantly improves joint function and quality of life, particularly in complex patients with depressive tendencies or those refractory to traditional NSAIDs [275,[277], [278], [279]]. Consequently, by integrating neuro-modulation with anti-inflammatory effects, duloxetine offers a comprehensive therapeutic paradigm for OA patients within the geriatric comorbidity network. Collectively, these pharmacological agents highlight a paradigm shift from symptom-oriented treatment to mechanism-based, comorbidity-integrated therapy in OA. Rather than targeting isolated joint pathology, these drugs act on shared biological pathways—including inflammation, metabolic dysregulation, bone remodeling, and cellular stress—that link OA with major chronic diseases in elderly populations. This integrated therapeutic framework not only provides a mechanistic rationale for drug repurposing but also underscores the importance of patient stratification based on dominant pathological phenotypes. Future research should focus on identifying these phenotypes to optimize personalized treatment strategies for OA within the geriatric comorbidity network. Conclusion OA, as a prevalent degenerative disease, represents a critical component of the aging population's health burden, often coexisting with a range of chronic conditions in the geriatric comorbidity network. This intricate web of interactions not only accelerates the progression of OA but also complicates its clinical management, as the pathological mechanisms underlying OA are deeply intertwined with factors such as inflammation, metabolic dysregulation, and altered mechanical forces. The concurrent presence of conditions like osteoporosis, obesity, diabetes, and hypertension exacerbates joint degeneration through multifactorial pathways, amplifying both the severity of symptoms and the challenges in treatment. Moreover, OA also significantly impacts other geriatric comorbidities, including osteoporosis, neurodegenerative diseases, cardiovascular diseases, and anxiety and depression, thereby further complicating the overall health and treatment of elderly patients via bidirectional organ crosstalk. While existing research has elucidated various aspects of these interrelationships, there remains a pressing need for deeper exploration into the molecular and systemic interactions that drive the onset and progression of OA within the context of geriatric comorbidities. Moreover, the therapeutic potential of medications commonly used in the treatment of these comorbidities, such as BPs, metformin, and statins, offers promising avenues for more holistic treatment strategies. Moving forward, a more integrated approach to both OA and its comorbidities, supported by targeted therapies and a deeper understanding of their shared pathophysiology, will be essential in improving the quality of life and functional outcomes for elderly patients. Comprehensive and interdisciplinary research is crucial to unravel these complex interactions, paving the way for more effective and personalized treatment paradigms that address the unique needs of aging populations. Author contribution Conceptualization: Hui Xie and Zhenxing Wang. Visualization: Haiyang Hu. Writing - original draft: Haiyang Hu, Hao Yin, Yiwei Liu. Writing - review & editing: Hui Xie and Zhenxing Wang. All authors have read and approved the final manuscript and agree to its publication in the journal. Declaration of generative AI and AI-assisted technologies in thewriting process Generative artificial intelligence (AI) and AI-assisted technologies were used to improve readability and language. Funding statement This work was supported by the National Natural Science Foundation of China (Grant No. 82125023 to Hui Xie, 82272562 and 82472523 to Zhen-Xing Wang), the Science and Technology Innovation Program of Hunan Province (Grant No. 2023RC3075 to Zhen-Xing Wang). Declaration of interest statement The authors declare no conflict of interest related to this article. Acknowledgements We thank everyone on the team for their great effort. Contributor Information Zhen-Xing Wang, Email: wangzx@csu.edu.cn. Hui Xie, Email: huixie@csu.edu.cn. Data availability Data sharing not applicable to this article as no datasets weregenerated or analyzed during the current study. References Associated Data Data Availability Statement Data sharing not applicable to this article as no datasets weregenerated or analyzed during the current study.